CRB-0401 is under clinical development by China Resources Pharmaceutical Group and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CRB-0401’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CRB-0401 overview
CRB-0401 is under development for the treatment of non-small cell lung cancer.
China Resources Pharmaceutical Group overview
China Resources Pharmaceutical Group (CRPGL) is a pharmaceutical company, which offers a range of nutritional supplements. The company involves in the research and development, manufacture, and also distribution of whole-drug products. Its products comprise chemical medicines, biologics, and health food and traditional Chinese medicine, and nutritional products. CRPGL offers products in the form of oral solid dosage, injections, large infusion bags, oral liquid dosage, powder vials, and topical preparations. The company markets its products through logistics, wholesale, retail, and supply chain services in various provinces across China. It supplies products to pharmaceutical dispensers and manufacturers, including distributors, retail pharmacies, and hospitals. CRPGL is headquartered in Wanchai, Hong Kong.
For a complete picture of CRB-0401’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
